Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation (EXPLORE MR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04098328
Recruitment Status : Recruiting
First Posted : September 23, 2019
Last Update Posted : March 11, 2020
Sponsor:
Information provided by (Responsible Party):
Polares Medical SA

Brief Summary:
Early feasibility study, single-arm registry design

Condition or disease
Mitral Regurgitation Mitral Valve Disease Mitral Valve Insufficiency

Detailed Description:
First-In-Human

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 12 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Early Feasibility EXperience of Posterior Leaflet RestOration to REduce Mitral Regurgitation (EXPLORE MR)
Actual Study Start Date : January 1, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2025



Primary Outcome Measures :
  1. Primary safety endpoint [ Time Frame: 30 days ]
    All-cause mortality

  2. Improvement from baseline mitral regurgitation [ Time Frame: 30 days ]
    Grade 2+ or less as evaluated by 2D transthoracic echocardiography


Secondary Outcome Measures :
  1. Technical success according to MVARC2 criteria [ Time Frame: 24 hours ]
    • Absence of procedure mortality
    • Successful access, delivery and retrieval of investigation delivery system
    • Successful deployment and correct positioning of intended implant(s)
    • Freedom from emergency surgery/re-intervention related to device or access procedure

  2. Procedure success according to MVARC2 criteria [ Time Frame: 30 days ]
    • Absence of procedure mortality or stroke
    • Proper placement and positioning of device
    • Freedom from unplanned re-intervention related to device or access procedure
    • Continued intended safety and performance of the device:

      • No evidence of structural or functional failure
      • No device technical failure issues/complications
      • MR reduction to moderate or less without stenosis
    • Absence of major device or procedure-related SAE:

      • Death
      • Stroke
      • Life-threatening bleed
      • Major vascular complication
      • Major cardiac structural complication
      • No device technical failure issues/complications
      • Stage 2 or 3 AKI
      • MI or coronary ischemia requiring PCI or CABG
      • Shock, heart or respiratory failure requiring IV vasopressors, mechanical intervention or prolonged intubation
      • Valve-related dysfunction, migration, thrombosis, or other complication requiring surgery or repeat intervention

  3. Device success according to MVARC2 criteria [ Time Frame: 30 days, 6 and 12 months, and 2 - 5 years post treatment ]
    • Absence of procedure mortality or stroke
    • Proper placement and positioning of device
    • Freedom from unplanned re-intervention related to device or access procedure
    • Continued intended safety and performance of the device:

      • No evidence of structural or functional failure
      • No device technical failure issues/complications
      • MR reduction to moderate or less without stenosis

  4. Patient success according to MVARC2 criteria [ Time Frame: 30 days, 6 and 12 months, and 2 - 5 years post treatment ]
    • Device success
    • Patient returned to pre-procedure setting
    • No rehospitalization or reintervention for mitral regurgitation or heart failure
    • Functional improvement from baseline by one or more NYHA class
    • 6MWT improvement from baseline by 50 metres or more

  5. Rate (%) of major adverse events as defined by MVARC2 criteria [ Time Frame: Procedure, discharge/7 days, 30 days, 6 and 12 months, and 2 - 5 years post treatment ]
    All-cause mortality, hospitalization due to cardiac conditions, stroke or TIA, myocardial infarction, access site and vascular complications, bleeding complications, acute kidney injury up to 7 days post-procedure, and arrhythmias and conduction system disturbances



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Inoperable or high surgical risk patients with symptomatic degenerative or functional mitral regurgitation (Grade 3+ or higher) with mitral valve anatomy deemed unsuitable, or off-label, to be treated with an approved edge-to-edge repair system.
Criteria

Inclusion Criteria:

  1. 18 years of age or older.
  2. Greater than moderate degenerative or functional mitral regurgitation (Grade 3+ or higher) as confirmed by transesophageal echocardiography (TEE) within 90 days prior to study procedure
  3. Patient must present with an STS Score less than 10%
  4. High surgical risk for conventional mitral repair or replacement due to morphological criteria (e.g. leaflet or annulus calcifications) as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure
  5. Mitral valve anatomy deemed unsuitable to be treated with an approved edge-to-edge repair system (e.g., retracted posterior leaflet, lack of leaflet tissue, calcified or cleft posterior leaflet) as assessed by the local heart team comprised of a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in treating mitral valve disease and heart failure
  6. Patient is approved by an independent Patient Eligibility Committee
  7. New York Heart Association (NYHA) Functional Class III or IV
  8. Patient willing to participate in study and provide signed EC-approved informed consent.
  9. Treating physician and patient agree that patient is able to return for all required post- procedure follow-up visits
  10. Women of child-bearing potential have a negative pregnancy test

Exclusion Criteria:

  1. Severe tricuspid regurgitation
  2. Severe aortic stenosis or insufficiency
  3. Severe mitral annulus calcification
  4. Diseased mitral anterior leaflet such as flail / prolapse/ heavy calcification
  5. Implanted vena cava filter
  6. Femoral veins with severe angulation and calcification
  7. Contraindication for transesophageal echocardiography (TEE) or MDCT scan.
  8. Active infection or endocarditis
  9. Previous mitral valve surgery
  10. Prior orthotopic heart transplantation
  11. Pulmonary artery systolic hypertension > 70mmHg
  12. Evidence of intra-cardiac, inferior vena cava (IVC) or femoral venous thrombus
  13. Left ventricular ejection fraction (LVEF) < 30%
  14. Implant or revision of any pacing device < 30 days prior to intervention
  15. Symptomatic coronary artery disease treated < 30 days prior to study procedure
  16. Myocardial infarction requiring intervention < 30 days prior to study procedure
  17. Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis), hypertrophic or restrictive cardiomyopathies, and constrictive pericarditis
  18. Active peptic ulcer or upper gastrointestinal bleeding < 90 days prior to study procedure
  19. Stroke < 180 days prior to study procedure
  20. Severe renal insufficiency (creatinine > 3.0 mg/dL) or patient requiring dialysis
  21. Cardiogenic shock at time of enrolment
  22. Hemodynamic instability requiring inotropic support or mechanical heart assistance
  23. Concurrent medical condition with a life expectancy of less than 2 years
  24. Pregnancy at time of enrolment
  25. History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3,000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
  26. Known hypersensitivity or contraindication to aspirin, heparin, ticlopidine or clopidogrel, nitinol, tantalum or allergy to contrast agents that cannot be pre-medicated
  27. Severe dementia or lack of capacity due to conditions that result in either inability to provide informed consent for the trial/procedure, prevent independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up assessments
  28. Emergency situations
  29. Company employees or their immediate family members
  30. Patient is under guardianship
  31. Patient is participating in another clinical study for which follow-up is currently ongoing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04098328


Contacts
Layout table for location contacts
Contact: Laura A Brenton +1 313 919 8044 labrenton1@gmail.com

Locations
Layout table for location information
Switzerland
Inselspital Bern Recruiting
Bern, Switzerland, 3010
Contact: Fabien Praz, MD         
Sponsors and Collaborators
Polares Medical SA
Investigators
Layout table for investigator information
Study Director: Laura A Brenton Polares Medical
Principal Investigator: Ulrich Schaefer, MD MarienKrankenhaus & Asklepios Klinik St. Georg, Hamburg (DE)
Principal Investigator: Stephan Windecker, MD Inselspital Bern, Bern (CH)
Layout table for additonal information
Responsible Party: Polares Medical SA
ClinicalTrials.gov Identifier: NCT04098328    
Other Study ID Numbers: 201901
First Posted: September 23, 2019    Key Record Dates
Last Update Posted: March 11, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitral Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases